培高利特治疗晚期帕金森病的长期经验。

Long-term experience with pergolide therapy of advanced parkinsonism.

作者信息

Kurlan R, Miller C, Levy R, Macik B, Hamill R, Shoulson I

出版信息

Neurology. 1985 May;35(5):738-42. doi: 10.1212/wnl.35.5.738.

DOI:10.1212/wnl.35.5.738

Abstract

Nine patients with idiopathic Parkinson's disease were treated with pergolide to a daily maintenance dose of 2.2 +/- 0.9 mg (mean +/- SD) for 17.3 +/- 8.3 months. After 1 month, there was an average 68% increase in mobile on-time, but the improvement declined to 30% by 6 months, 23% by 1 year, and virtually disappeared by 18 months of therapy. Pergolide was discontinued in seven patients because of loss of efficacy (4 patients), confusion (1 patient), or myocardial infarction or ventricular ectopy (2 patients). Partial but temporary restoration of mobility was observed in seven patients who were switched to an alternate-day dosing schedule after 9.2 +/- 2.4 months. Two patients with advanced Shy-Drager syndrome were treated with pergolide without benefit.

摘要

9例特发性帕金森病患者接受培高利特治疗，每日维持剂量为2.2±0.9毫克（均值±标准差），疗程为17.3±8.3个月。1个月后，可活动时间平均增加68%，但到6个月时改善程度降至30%，1年时为23%，治疗18个月时几乎消失。7例患者因疗效丧失（4例）、意识模糊（1例）或心肌梗死或室性早搏（2例）而停用培高利特。9.2±2.4个月后改为隔日给药方案的7例患者，观察到活动能力部分但暂时恢复。2例晚期夏伊-德雷格综合征患者接受培高利特治疗无效。